{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:27:44Z","timestamp":1793485664734,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jdiacomp.2026.109393","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:30:05Z","timestamp":1787585405000},"page":"109393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of sodium-glucose cotransporter 2 inhibitors after acute myocardial infarction: Are the benefits limited to patients with diabetes? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"40","author":[{"given":"Marcel Cat\u00e3o F.","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora","family":"Mamede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Bessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Carvalhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Ar\u00eaa","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoela","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2026.109393_bb0005","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.111.032698","article-title":"New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute workshop","volume":"124","author":"Schwartz Longacre","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/HCQ.0000000000000032","article-title":"AHA\/ACC clinical performance and quality measures for adults with ST-elevation and non\u2013ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures","volume":"10","author":"Jneid","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0015","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0002-8703(99)70320-0","article-title":"Clinical epidemiology of acute myocardial infarction","volume":"138","author":"Tavazzi","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0140-6736(13)61452-X","article-title":"Future treatment strategies in ST-segment elevation myocardial infarction","volume":"382","author":"Windecker","year":"2013","journal-title":"The Lancet"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0b013e3182742cf6","article-title":"ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"Writing Committee Members","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/cd23-as01","article-title":"Standards of Care in Diabetes\u20142023 abridged for primary care providers","volume":"41","author":"American Diabetes Association","year":"2023","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0035","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0040","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0045","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2024"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0060","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0065","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: the EMMY trial","volume":"43","author":"Von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0070","doi-asserted-by":"crossref","DOI":"10.1177\/10742484241252474","article-title":"Safety and efficacy of early SGLT2 inhibitors initiation in diabetic patients following acute myocardial infarction, a retrospective study","volume":"29","author":"Moady","year":"2024","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0075","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cpt.3304","article-title":"Clinical outcomes in type 2 diabetes patients after acute myocardial infarction: a comparison of sodium\u2013glucose cotransporter 2 inhibitors vs. non-users","volume":"116","author":"Lee","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0080","article-title":"SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART","volume":"45","author":"Ros\u00e9n","year":"2024","journal-title":"Lancet Reg Health - Eur"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwae175.075","article-title":"Efficacy and safety of dapagliflozin in non-diabetic patients with anterior wall ST-segment elevation acute myocardial infarction (STEMI) in early-hospital period","volume":"31","author":"Hayrapetyan","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0090","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00228-024-03623-7","article-title":"Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients","volume":"80","author":"Cai","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0095","first-page":"1427","article-title":"Effect of dapagliflozin on cardiac function and MACE in elderly patients with heart failure after acute myocardial infarction","volume":"48","author":"Liu Kanling","year":"2023","journal-title":"Med J Chin Peoples Lib Army"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0100","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00228-023-03495-3","article-title":"Dapagliflozin reduces risk of heart failure rehospitalization in diabetic acute myocardial infarction patients: a propensity score-matched analysis","volume":"79","author":"Mao","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027824","article-title":"Sodium-glucose cotransporter-2 inhibitors after acute myocardial infarction in patients with type 2 diabetes: a population-based investigation","volume":"12","author":"Kwon","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102213","article-title":"Effect of dapagliflozin on epicardial fat volume in patients with acute coronary syndrome assessed by computed tomography","volume":"49","author":"Mac\u00edas-Cervantes","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-022-01627-0","article-title":"Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"21","author":"Zhu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0125","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154936","article-title":"Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts","volume":"127","author":"Marfella","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106448","article-title":"Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes","volume":"184","author":"Marfella","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-023-01814-7","article-title":"SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis","volume":"22","author":"Sardu","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080904","article-title":"Metformin therapy effects on the expression of sodium-glucose cotransporter 2, leptin, and SIRT6 levels in pericoronary fat excised from pre-diabetic patients with acute myocardial infarction","volume":"9","author":"Sardu","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12933-022-01506-8","article-title":"Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry","volume":"21","author":"Paolisso","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2026.109393_bb0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12916-023-02781-2","article-title":"SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"21","author":"Marfella","year":"2023","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.jdiacomp.2026.109393_bb9000","first-page":"3","article-title":"Supplement article european journal of heart failure, [S.L.]","volume":"24","author":"Brito","year":"2022"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726001388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872726001388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:28:45Z","timestamp":1788834525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872726001388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1056872726001388"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109393","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of sodium-glucose cotransporter 2 inhibitors after acute myocardial infarction: Are the benefits limited to patients with diabetes? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109393"}}